Namrata Saroj, OD.

BEDFORD, Mass.—Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company that develops therapies for retinal diseases and other eye conditions, has named Namrata Saroj, OD as chief business officer (CBO). Dr. Saroj previously served as a development strategy consultant to Ocular since February 2024. According to the announcement, Dr. Saroj brings over 20 years of experience focusing on the global development and commercialization of drugs and technologies advancing ophthalmic care. The company noted that her extensive understanding of the ophthalmology clinical and commercial landscapes is founded on her diverse experiences working across multiple programs.

Additionally, she has collaborated with several companies across various stages, from early-stage start-ups to late-stage development and commercialization. In this capacity, she has effectively helped these companies with strategic partnerships, clinical development, trial enrollment, launch preparation and commercialization support.

“I am thrilled to further strengthen and enrich Ocular’s senior leadership team with the appointment of Namrata as chief business officer," said Pravin U. Dugel, MD, executive chairman, president and chief executive officer of Ocular Therapeutix. "She brings a unique perspective to the role of CBO based on her track record in clinical development, launch preparation and commercialization. Namrata has contributed to the success of multiple major FDA-approved drugs for ophthalmic diseases and has meaningfully enhanced the effective execution of our ongoing registrational program for Axpaxli in wet age-related macular degeneration (wet AMD).

"I am confident that Namrata’s broad retina community connections and keen understanding of the commercial landscape will be extremely valuable to our future success and a significant asset to her work as CBO as we seek to fulfill our vision of being a leading retina company,” Dr. Dugel said.

The company stated that Dr. Saroj has been a major contributor toward the development and commercialization of Lucentis and Eylea, two of the company’s most successful products in this sector. The company added that Dr. Saroj is well recognized in the retina community for her work in clinical development collaboration with investigators and industry experts on clinical trial designs and execution. She has co-authored seminal peer-reviewed publications in the management of retinal diseases.

“Advancing innovative treatments for patients has been the focus of my entire career. I joined Ocular to apply my expertise in ophthalmology drug development to advance Axpaxli in wet AMD and beyond,”  Dr. Saroj, said. “Having worked as a consultant to Ocular, I have been fortunate to participate in the assembly of this top-notch team of retina experts, and I am excited to now dedicate my time to the organization going forward. In my new role as chief business officer, I am delighted to have the opportunity to leverage my experience in clinical execution, market strategy and pipeline expansion to contribute to Ocular’s growth and support the company’s mission of improving vision for patients.”

In addition to her work with Ocular Therapeutix, Dr. Saroj is also the co-founder of Clinical Trials Resource Group, a contract research organization focused on executing ophthalmology clinical trials. 

Previously, she led the Ophthalmology Medical Affairs team as an executive director at Regeneron Pharmaceuticals, Inc. Dr. Saroj has previously held positions at Genentech, Inc. and Manhattan Eye, Ear & Throat Hospital. She is the president of the Association for Macular Diseases, a non-profit organization offering support to individuals, their families, friends and the professional community.